A Phase 2b Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)
Status:
Not yet recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of zetomipzomib (30 mg or 60
mg) compared with placebo in achieving renal response after 52 weeks of treatment in patients
with active lupus nephritis (LN).